Evidence map›Paper›PMID 19770625›Full record

Trial reportAmerican journal of clinical oncology2010

S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Charles D Blanke, Kari Chansky, Kathy L Christman, Scott A Hundahl, Brian F Issell, Peter J Van Veldhuizen, G Thomas Budd, James L Abbruzzese, John S Macdonald

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Charles D BlankeDivision of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC. cblanke@bccancer.bc.ca
Kari Chansky
Kathy L Christman
Scott A Hundahl
Brian F Issell
Peter J Van Veldhuizen
G Thomas Budd
James L Abbruzzese
John S Macdonald
BC Cancer Agency · CACancer Research And Biostatistics · USCatholic Medical Center · USPrisma Health · USScripps Health · USSWOG Cancer Research Network · USUniversity of California Davis Medical Center · USUniversity of Kansas · US

Funding

SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
SOUTHWEST ONCOLOGY GROUP--STATISTICAL CENTERU10CA038926 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEBLANC, MICHAEL L. · 1985 to 2013
$69.8M
COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035431 · NCI · VIA CHRISTI REGIONAL MEDICAL CENTER · PI DAKHIL, SHAKER R · 1985 to 2014
$24.0M
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035119 · NCI · SPARTANBURG REGIONAL MEDICAL CENTER · PI BEARDEN, JAMES D · 1985 to 2013
$21.5M
WESTERN ONCOLOGY RESEARCH CONSORTIUMU10CA045377 · NCI · PROVIDENCE PORTLAND MEDICAL CENTER · PI CONLIN, ALISON K · 1987 to 2013
$9.9M
Hawaii Minority-Based Clinical Community Oncology ProgramU10CA063844 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI BERENBERG, JEFFREY LEE · 1994 to 2014
$9.0M
OZARKS REGIONAL COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA045560 · NCI · ST. JOHN'S REGIONAL HEALTH CENTER · PI CARLSON, JAY W · 1987 to 2014
$8.2M
KANSAS CITY COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035176 · NCI · NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM · PI GAUR, RAKESH · 1985 to 2014
$8.0M
Montana Cancer Consortium CCOPU10CA067575 · NCI · MONTANA CANCER CONSORTIUM · PI MARCHELLO, BENJAMIN T. · 1995 to 2013
$6.5M
LSU MEDICAL CENTER MINORITY CCOPU10CA063845 · NCI · LSU HEALTH SCIENCES CENTER · PI VEITH, ROBERT W · 1994 to 2014
$6.4M
TUMOR INSTITUTE CCOPU10CA045461 · NCI · BAY AREA TUMOR INSTITUTE · PI FEUSNER, JAMES · 1989 to 2014
$6.3M
VIRGINIA MASON COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035192 · NCI · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI NICHOLS, CRAIG RANDAL · 1985 to 2014
$6.2M
NCI NIH HHS CA12644NCI NIH HHS CA20319NCI NIH HHS CA22433NCI NIH HHS CA35192NCI NIH HHS CA35996NCI NIH HHS CA42777NCI NIH HHS CA45377NCI NIH HHS CA45461NCI NIH HHS CA46113NCI NIH HHS CA46136NCI NIH HHS CA46282NCI NIH HHS CA46368NCI NIH HHS CA52757NCI NIH HHS CA58658NCI NIH HHS CA58686NCI NIH HHS CA63845NCI NIH HHS CA76429NCI NIH HHS N01 CA004919NCI NIH HHS N01 CA027057NCI NIH HHS N01 CA032102NCI NIH HHS N01 CA035119NCI NIH HHS N01 CA035176NCI NIH HHS N01 CA035431NCI NIH HHS N01 CA038926NCI NIH HHS N01 CA045560NCI NIH HHS N01 CA063844NCI NIH HHS N01 CA067575NCI NIH HHS U10 CA004919NCI NIH HHS U10 CA012644NCI NIH HHS U10 CA020319NCI NIH HHS U10 CA022433NCI NIH HHS U10 CA027057NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA035119NCI NIH HHS U10 CA035176NCI NIH HHS U10 CA035192NCI NIH HHS U10 CA035431NCI NIH HHS U10 CA038926NCI NIH HHS U10 CA042777NCI NIH HHS U10 CA045377NCI NIH HHS U10 CA045461NCI NIH HHS U10 CA045560NCI NIH HHS U10 CA046113NCI NIH HHS U10 CA046282NCI NIH HHS U10 CA046368NCI NIH HHS U10 CA052654NCI NIH HHS U10 CA058686NCI NIH HHS U10 CA063844NCI NIH HHS U10 CA063845NCI NIH HHS U10 CA067575
6 · The paper itself

Abstract

objectiveThe primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting.

methodsPatients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression.

resultsCharacteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69% of 31%; performance status 0/1/2 15/20/1. The confirmed response rate was 19%, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia.

conclusionsThis regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFluorouracilHumansLeucovorinMaleMiddle AgedNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeTrimetrexateFluorouracilLeucovorinTrimetrexate

Identifiers

PMID19770625
PMCPMC2967385
OpenAlexW2029339227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.